Perspective Therapeutics, Inc. (CATX)

Nyse Mkt Llc • Healthcare

$2.66

-$0.04 (-1.8%)

Market closed

Last close at October 9, 2026 at 20:00 UTC

Open$2.71

Day Range$2.63 - $2.76

Avg. Volume (3M)2.6M

Market Cap$303.3M

52 Week Range

$1.96$6.16

Next EarningsIn 30 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$81K100%

Gross Profitminus cost of goods$81K100%

Fundamentals & Financials

Revenue (TTM)

$366K

Net Income (TTM)

-$116.4M

EPS (TTM)

-$1.56

ROA (TTM)

-29.7%

Current Ratio

6.61

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

0.0%Q3 2025-$0.3

-6.1%Q4 2025-$0.35

-37.8%Q1 2026-$0.51

+13.8%Q2 2026-$0.25

+12.4%Q3 2026-$0.22

Nov 9

in 30 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +12.4%

Perspective Therapeutics beat consensus on adjusted EPS in the second fiscal quarter of 2026, reported Aug. 10 based on preliminary results, with adjusted EPS of -$0.22 versus the -$0.25 estimate, about +12% and up from -$0.30 a year ago. Gross profit came in at about $1.1 million, while net income was a loss of about $26.8 million, wider than the $21.5 million loss a year earlier by 24.7%; operating cash flow was negative $20.6 million. Consensus for the next period calls for EPS of -$0.26 on revenue of $89,871.00.

Next report — what to expect

Perspective Therapeutics, Inc. (CATX) is set to report earnings on November 9, 2026. Wall Street expects EPS of -$0.24 on revenue of $62,149.00. For trailing context, revenue fell -72.1% year over year last quarter. CATX has beaten EPS in 3 of 8 most recent quarters.

View full earnings history

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. trades on the NYSE American as CATX and operates in healthcare as a small-cap company focused on cancer treatment technologies. Its offerings span radiopharmaceutical products and medical devices for cancer and other serious malignant conditions, and include CS-1 Cesium-131 brachytherapy seeds.

Name

Perspective Therapeutics, Inc.

CEO

Johan Spoor

Website

www.perspectivetherapeutics.com

Industry

Healthcare

Year Founded

1998

Employees

165

Today's Snapshot

AI-generated

CATX closed 1.9% lower at 2.66, against a firmer sector. Volume was about half of its usual level. Perspective Therapeutics received Fast Track status from the FDA, the U.S. drug regulator, for PSV359, a cancer treatment.

Trading Volume

Below 10d avg (2.1M)

1.1M

vs S&P 500 Today

Underperforming Market

-2.44%

Updated: October 9, 2026 at 20:31 UTC

Technical Indicators

1 Buy3 Neutral4 Sell

CATX is trading near 2.66 and shows a sell bias driven by price sitting below most medium- and long-term moving averages despite a touch of short-term support. Trend strength is weak, as ADX is low, and momentum measures are essentially flat with only marginal positive momentum but a neutral MACD. Volatility is relatively high on a percentage basis per ATR, which is flagged as a concern, and on-balance volume aligns with the downside. The classic pivot lies near the market without providing clear support. Technical takeaway: Sell — longer-term averages and volume favor downside despite short-term lift.

All signals

EMA (5 indicators)$2.63 - $3.30
Sell
RSI (14)46.75
Neutral
Stochastic %K (14, 3, 3)42.69
Neutral
MACD Level (12, 26)-0.11
Neutral

Peers & Related Assets

NVCRNovocure Ltd

$14.58+2.5%

ARAYAccuray Incorporated

$0.23-4.8%

DCTHDelcath Systems, Inc.

TLSITriSalus Life Sciences, Inc.

SRTSSensus Healthcare, Inc.

ITOCiTonic Holdings Ltd.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.